2005
DOI: 10.1016/j.addr.2005.07.018
|View full text |Cite
|
Sign up to set email alerts
|

ES cell technology: An introduction to genetic manipulation, differentiation and therapeutic cloning

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2005
2005
2015
2015

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(7 citation statements)
references
References 101 publications
0
7
0
Order By: Relevance
“…In the past decade, ESCs have also been obtained from nonhuman primate and human embryos (Thomson and Kalishman, 1998;Sasaki et al, 2005;Suemori et al, 2001). Human ES cells (hESCs) are potentially valuable for the provision of therapeutic cells whose growth and differentiation can be controlled for the treatment of disease (Hook et al, 2005;Liew et al, 2005). However, for ESC-based therapy to become a clinical reality, translational research involving nonhuman primates is essential because of the many regulations and ethical considerations surrounding the use of hESCs.…”
Section: Introductionmentioning
confidence: 99%
“…In the past decade, ESCs have also been obtained from nonhuman primate and human embryos (Thomson and Kalishman, 1998;Sasaki et al, 2005;Suemori et al, 2001). Human ES cells (hESCs) are potentially valuable for the provision of therapeutic cells whose growth and differentiation can be controlled for the treatment of disease (Hook et al, 2005;Liew et al, 2005). However, for ESC-based therapy to become a clinical reality, translational research involving nonhuman primates is essential because of the many regulations and ethical considerations surrounding the use of hESCs.…”
Section: Introductionmentioning
confidence: 99%
“…Undifferentiated ES cells are frequently regarded as a potential starting material for regenerative medicine applications or for biological, pharmacological and toxicological studies in vitro as a reliable alternative to animal models (Hook et al 2005;Pouton and Haynes 2005). Therefore, a deeper understanding of the factors affecting ES cell expansion and/or controlled differentiation is needed in order to develop scale-up strategies to produce a significant number of cells for such applications.…”
Section: Introductionmentioning
confidence: 99%
“…High-resolution genetic and physical linkage maps of the mouse genome have greatly facilitated the identification and cloning of mouse disease genes. Furthermore, transgenic approaches allowed us to ectopically express or make germline mutations in virtually any gene in the mouse genome by using homologous recombination in embryonic stem (ES) cells [2, 3]. Inbred, congenic and transgenic strains are widely used in current research labs as very valuable tools to investigate human diseases pathogenesis and develop new effective therapeutical strategies.…”
Section: Human Disease Mouse Modelsmentioning
confidence: 99%
“…Homologous recombination between genomic and the exogenous DNA is a very inefficient and rare process, but it takes place in ES cells with relatively higher efficiency than it does in other cell types [4]. Gene targeting by homologous recombination in ES cells has improved our ability to study many biological processes [3]. Since ES cells contribute to all tissues upon injection into a recipient blastocyst, including the germline [6, 7] modification in an ES cell genome can be transmitted, by the breeding of ES cell/wild-type chimaeras, to generate mice containing the desired mutations in all cells.…”
Section: Embryonic Stem (Es) and Induced Pluripotent Stem (Ips) Cellsmentioning
confidence: 99%
See 1 more Smart Citation